Cingulate appoints Bryan Downey as chief commercial officer

Cingulate Inc. (NASDAQ: CING) appointed Bryan Downey as Chief Commercial Officer as the company prepares for potential commercialization of its ADHD treatment CTx-1301. The appointment follows the FDA's acceptance of the company's New Drug Application for review, with a target action date of May 31, 2026.

Downey brings over 25 years of commercial strategy experience, including senior roles at Alfasigma USA, Jubilant Pharma, and nearly two decades at Sanofi, where he served as Vice President and Head of the U.S. Cardiovascular and Allergy Business Unit. Most recently, he worked as Managing Director in CRA | Admired Leadership's Leadership Advisory Practice.

The Kansas City-based biopharmaceutical company also completed a $6 million financing transaction through an 18-month promissory note with 9% annual interest. The funding extends the company's cash runway into the second quarter of 2026.

CTx-1301 utilizes Cingulate's Precision Timed Release platform to deliver three timed releases of dexmethylphenidate HCI from a single daily tablet for ADHD treatment. The company has partnered with Indegene to establish commercial infrastructure for the potential product launch.

On November 3, the company granted Downey stock options to purchase 30,000 shares at $3.80 per share, vesting over four years. The grant was approved as an inducement award under Nasdaq listing rules.

The promissory note provides Cingulate flexibility to begin monthly redemptions after the May 2026 PDUFA date. Proceeds will be used for working capital and general corporate purposes, according to the company's statement.

You May Also Be Interested In